Orchestra BioMed Holdings, Inc. (OBIO) Key Metrics
OBIO valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $327.6M
- Enterprise value
- $282.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 10.2 10-yr median 55.8
- Price / book
- 18.4 10-yr median 4.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.52
OBIO key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsOBIO valuation Price multiples at each fiscal year-end price.
Price / sales−89.4%
5.9
2025 · hover or tap a bar for each year
20202025
Price / book−30.0%
3.1
2025 · hover or tap a bar for each year
20202025
Free cash flow yield+9.6 pts
−25.0%
2025 · hover or tap a bar for each year
20202025
OBIO returns How much profit the business earns on the capital it uses.
Return on equity+11.4 pts
−109.4%
2025 · hover or tap a bar for each year
20202025
Return on assets+16.0 pts
−55.2%
2025 · hover or tap a bar for each year
20202025
Free cash flow margin
−147.7%
2025 · hover or tap a bar for each year
20202025
Asset turnover+1,038.7%
0.35
2025 · hover or tap a bar for each year
20202025
OBIO per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+878.8%
$0.70
2025 · hover or tap a bar for each year
20202025
Earnings per share
−$1.10
2025 · hover or tap a bar for each year
20202025
Free cash flow per share
−$1.04
2025 · hover or tap a bar for each year
20202025
Book value per share+48.3%
$1.33
2025 · hover or tap a bar for each year
20202025
Shares outstanding+29.7%
47.7M
2025 · hover or tap a bar for each year
20202025
OBIO financial health Debt, liquidity and how easily interest is covered.
Debt / equity−49.8%
0.25
2025 · hover or tap a bar for each year
20202025
Net debt−$40.3M
−$90.6M
2025 · hover or tap a bar for each year
20202025
Current ratio+51.1%
6.45
2025 · hover or tap a bar for each year
20202025
Interest coverage
-45.1
2025 · hover or tap a bar for each year
20202025
Debt / assets−36.0%
0.14
2025 · hover or tap a bar for each year
20202025
OBIO efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−12 days
1 days
2025 · hover or tap a bar for each year
20202025
Days of inventory+179 days
464 days
2025 · hover or tap a bar for each year
20202025
Days payables outstanding+3,598 days
10,786 days
2025 · hover or tap a bar for each year
20202025
Cash conversion cycle−3,432 days
-10,321 days
2025 · hover or tap a bar for each year
20202025
Capex / revenue−9.5 pts
1.5%
2025 · hover or tap a bar for each year
20202025
OBIO valuation history
Fiscal year-endToday6-year median
OBIO returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OBIO debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OBIO cash returned to shareholders
DividendsBuybacksFree cash flow
OBIO price vs earnings per share
Share price at year-endEPS (right axis)
OBIO key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $198.2M | $147.3M | $303.3M | $254.2M | $206.1M | $262.0M |
| Enterprise value | $107.6M | $97.0M | $217.4M | $182.3M | $200.9M | $235.6M |
| Price / sales | 5.9 | 55.8 | 109.9 | 72.0 | — | 45.9 |
| Price / book | 3.1 | 4.5 | 4.5 | 4.8 | — | — |
| EV / sales | 3.2 | 36.8 | 78.8 | 51.6 | — | 41.3 |
| Earnings yield | −26.6% | −41.4% | −16.2% | −13.2% | −11.2% | −8.2% |
| Free cash flow yield | −25.0% | −34.5% | −15.2% | −11.8% | −9.6% | −10.2% |
| Shareholder yield (dividends + buybacks) | — | — | — | 36.4% | — | — |
| Share price at fiscal year-end | $4.15 | $4.00 | $9.13 | $9.98 | $10.08 | $12.81 |
| Per share | ||||||
| Revenue per share | $0.70 | $0.07 | $0.08 | $0.14 | $0.00 | $0.28 |
| Earnings per share | −$1.10 | −$1.66 | −$1.48 | −$1.32 | −$1.13 | −$1.04 |
| Operating cash flow per share | −$1.03 | −$1.37 | −$1.39 | −$1.15 | −$0.95 | −$1.28 |
| Free cash flow per share | −$1.04 | −$1.38 | −$1.39 | −$1.17 | −$0.96 | −$1.31 |
| Cash per share | $2.23 | $1.81 | $2.64 | $3.29 | $0.53 | $1.75 |
| Book value per share | $1.33 | $0.90 | $2.05 | $2.06 | −$3.48 | −$2.37 |
| Tangible book value per share | $1.33 | $0.90 | $2.05 | $2.06 | −$3.48 | −$2.37 |
| Capex per share | $0.01 | $0.01 | $0.00 | $0.02 | $0.01 | $0.03 |
| Debt per share | $0.33 | $0.45 | $0.05 | $0.47 | $0.28 | $0.46 |
| Shares outstanding | 47.7M | 36.8M | 33.2M | 25.5M | 20.4M | 20.4M |
| Change in shares outstanding | +29.7% | +10.8% | +30.4% | +24.6% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −109.4% | −120.8% | −81.5% | — | — | — |
| Return on assets (ROA) | −55.2% | −71.2% | −51.5% | −61.6% | −89.2% | −56.1% |
| Return on tangible assets | −45.9% | −80.1% | −51.6% | −35.2% | −170.1% | −56.1% |
| Free cash flow margin | −147.7% | — | — | −845.7% | — | −468.6% |
| Financial health | ||||||
| Total debt | $16.0M | $16.5M | $1.7M | $11.9M | $5.7M | $9.5M |
| Cash & short-term investments | $106.5M | $66.8M | $87.6M | $83.8M | $10.9M | $35.8M |
| Net debt | −$90.6M | −$50.3M | −$85.9M | −$71.9M | −$5.2M | −$26.3M |
| Debt / equity | 0.25 | 0.50 | 0.02 | 0.23 | — | — |
| Debt / assets | 0.14 | 0.22 | 0.02 | 0.12 | 0.42 | 0.25 |
| Current ratio | 6.45 | 4.27 | 7.95 | 4.56 | 0.92 | 2.52 |
| Quick ratio | 6.43 | 4.26 | 7.94 | 4.55 | 0.92 | 2.52 |
| Interest coverage | -45.1 | — | — | — | -23.5 | — |
| Working capital | $91.2M | $53.0M | $77.9M | $66.1M | −$921,000 | $21.9M |
| Invested capital | −$27.2M | −$17.3M | −$17.9M | −$19.4M | −$76.5M | −$74.9M |
| Tangible asset value | $63.4M | $33.0M | $68.0M | $52.5M | −$71.2M | −$48.5M |
| Net current asset value | $56.4M | $26.0M | $61.9M | $41.7M | −$73.4M | −$50.4M |
| Graham net-net per share | $1.16 | $0.65 | $1.82 | $1.61 | −$3.61 | −$2.48 |
| Capital allocation | ||||||
| Share buybacks (net) | — | — | — | $92.6M | — | — |
| Capex / revenue | 1.5% | 11.0% | 2.8% | 16.7% | — | 9.5% |
| Capex / depreciation | 1.50 | 0.94 | 0.27 | 2.66 | 1.51 | 3.93 |
| Stock-based compensation / revenue | 35.8% | 402.4% | 276.3% | 96.6% | — | 3.9% |
| R&D / revenue | 173.8% | 1,622.6% | 1,225.4% | 621.1% | — | 236.3% |
| SG&A / revenue | 80.4% | 907.2% | 734.0% | 397.2% | — | 190.0% |
| Efficiency | ||||||
| Days sales outstanding | 1.0 | 13.2 | 12.9 | 11.2 | — | 10.8 |
| Days of inventory on hand | 463.9 | 285.4 | 414.1 | 195.0 | 125.6 | 173.7 |
| Days payables outstanding | 10,785.8 | 7,187.3 | 6,738.8 | 3,398.9 | 3,487.7 | 4,465.6 |
| Cash conversion cycle (days) | -10,320.8 | -6,888.7 | -6,311.8 | -3,192.7 | — | -4,281.1 |
| Receivables turnover | 358.10 | 27.62 | 28.31 | 32.56 | 0.00 | 33.95 |
| Payables turnover | 0.03 | 0.05 | 0.05 | 0.11 | 0.10 | 0.08 |
| Inventory turnover | 0.79 | 1.28 | 0.88 | 1.87 | 2.91 | 2.10 |
| Asset turnover | 0.35 | 0.03 | 0.03 | 0.06 | 0.00 | 0.15 |
| Average receivables | $93,500 | $95,500 | $97,500 | $108,500 | $144,500 | $168,000 |
| Average payables | $5.6M | $4.0M | $3.4M | $3.0M | $1.9M | $1.8M |
| Average inventory | $241,500 | $159,500 | $211,000 | $172,000 | $68,500 | $69,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from OBIO's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OBIO valuation and financial ratios
Orchestra BioMed earned a return on equity of −109.4% in fiscal 2025. It ended the year with $16.0 million of debt and $106.5 million in cash and short-term investments, a net cash position of $90.6 million. The share count rose 133.5% from 20.4M to 47.7M over 5 years.
See the OBIO income statement, the OBIO chart for price history, or the OBIO stock overview for the latest quote and news.
OBIO key metrics FAQ
What is Orchestra BioMed's return on equity?
Orchestra BioMed's return on equity (ROE) was −109.4% in fiscal 2025: net income of -$52.7 million on average shareholders' equity of $48.2 million.
How much debt does Orchestra BioMed have?
Orchestra BioMed had total debt of $16.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.25 and more cash than debt.
What is Orchestra BioMed's free cash flow yield?
Orchestra BioMed generated -$49.5 million of free cash flow in fiscal 2025, a free cash flow yield of −25.0% on its market value at year-end ($198.2 million).
What is Orchestra BioMed's current ratio?
Orchestra BioMed's current ratio was 6.45 at the end of fiscal 2025: current assets were 6.45 times current liabilities.